Boehringer Ingelheim is investing again in immuno-oncology, announcing a deal to acquire the San Diego-based biotechnology startup Nerio Therapeutics and its slate of preclinical drug candidates. Worth up to $1.3 billion, the acquisition hands Boehringer access to a research program the German pharmaceutical company envisions as a “potential key centerpiece” of its immuno-oncology drug portfolio. Nerio’s small molecule drugs are designed to block enzymes known as PTPN1 and PTPN2 that brake the body’s immune response to tumors.
Read the full article: Boehringer Adds to Cancer Drug Pipeline with Deal for Startup Nerio //
Source: https://www.biopharmadive.com/news/boehringer-ingelheim-nerio-acquire-checkpoint-inhibitor/722623/